Dr Shailesh Samal

Dr Shailesh Samal

Research & Development

Dr. Shailesh Kumar Samal has a double doctorate, a Ph.D. in Medical Sciences from Karolinska Institutet, Sweden, and a Ph.D. in Biochemistry from Maastricht University, Netherlands. He is the elected fullmember of Sigma Xi The most prestigious scientific research honor society of the world in 2024. He is also part of an international program called INTRICARE - Marie Skłodowska-Curie project by the European Union. His Ph.D. work was on Immune Mechanisms and Potential Immunological Treatment in Atherosclerosis. He is one of the India’s youngest Adjunct faculty/professor at Indian Institute of Technology, Ropar, India. He has received 3 prestigious international fellowships to study in the USA, Portugal, and Sweden. He has also worked with Prof. Oliver Smithies (Nobel laureate for Medicine-2007) at the University of North Carolina, Chapel-Hill, USA, and got another scholarship at Universidade Do Porto, Portugal, for 10 months under the Erasmus Mundus Euphrates scholarship program. Dr. Shailesh is a serial entrepreneur and co-founded many companies, such as Inflanova AB, Val- Infla, and Nordia Fresh AS, and took the lead on the scientific activities at Elemntoz Research and Valnizen Healthcare as a chief scientific officer. He is the CEO of Inflanova AB in Sweden. He got the Young Scientist title at the Lindau Nobel Laureates Meeting 2018, Germany. His active research is on specific natural antibodies against a small lipid epitope. Phosphorylcholine (anti-PC) is a protection marker for cardiovascular disease (CVD), atherosclerosis development, and other conditions with chronic inflammation such as Rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and chronic kidney disease (CKD). These conditions represent huge medical unmet needs. He has proposed the development of the old friends/hygiene hypothesis, where anti-PC is too low due to a lack of exposure to old pathogens, such as nematodes, parasites, and some bacteria, from an evolutionary point of view. Inflanova AB develops vaccines and diagnostics against chronic inflammatory conditions – a significant cause of disease. Further, we have made unexpected discoveries about covid-19 and other viral diseases. The novel inventions are based on combining novel information technologies with deep learning and experimental. Their inventions could improve the situation for many patients by vaccination, restoring protective anti-PC immunity.